Webinar

Development of a multiplex assay for prediction of immunotherapy response in metastatic melanoma patients

Watch Now

May 18 2022

On demand CEST

Online

Lunaphore webinar

Join Prof. Paolo Ascierto and Dr. Gabriele Madonna for an exclusive presentation during Melanoma Awareness Month.

At the end of the webinar, there will be a live Q&A session, giving the opportunity to ask your questions to our speakers.

Not available? Register anyway and access the webinar on demand.

May 18, 2022

Webinar

3:00 PM CEST

Online

Abstract:

Melanoma is the most aggressive among all skin cancers and is responsible for a high mortality rate. Combined immunotherapies have demonstrated greater efficacy in boosting the immune system of melanoma patients. However, the clinical decision on which combination to be used and which patients will benefit the most from it remains a challenge. Understanding the immune context of patients’ tumor and the identification of reliable biomarker redouts will assist clinicians in their decision. We developed a multiplex immunohistochemistry assay to profile the tumor microenvironment of metastatic melanoma patients who responded or did not to combined immunotherapy. We used LabSat®, an automated stainer based on Lunaphore’s microfluidic technology, to analyze the expression of PD-L1, CD8, and LAG-3. Our results provide first-time evidence of a different expression pattern of these markers between responder and non-responder melanoma patients.

Speakers

Prof. Paolo Ascierto

Prof. Paolo Ascierto

Director of the Unit of Melanoma

National Tumor Institute G. Pascale, Naples, Italy

Prof. Paolo Ascierto is a world-leading key opinion leader in immunotherapy. He is currently the Director of the Department of Melanoma, Cancer Immunotherapy, and Development Therapeutics at the National Cancer Institute in Naples, Italy. He is a Scientific Reviewer for leading medical journals and a Member of the Society of Melanoma Research’s Steering Committee. Dr. Ascierto is part of the Board of Directors for SITC and President of the Fondazione Melanoma Onlus & Campania Society of ImmunoTherapy of Cancer. He has presided as PI on over 150 clinical trials and is the author of more than 600 publications in peer-reviewed journals.

Dr. Gabriele Madonna

Dr. Gabriele Madonna

Health Researcher

National Tumor Institute G. Pascale, Naples, Italy

Dr. Gabriele Madonna is a Health Researcher at the Department of Melanoma at the National Cancer Institute in Naples. He earned his Ph.D. in Clinical and Experimental Medicine at the University of Naples, Italy. His initial research focused on the repair mechanisms for UV-induced DNA damage. Since 2010 his research interest has evolved into the study of Immunoscore and immune profiling in melanoma and the identification of potential predictive and prognostic biomarkers of response to immunotherapy and targeted therapy. He is the author of 40 peer-reviewed publications in international journals.

Related Events